In 2010, Poruk et al. showed that in pancreatic adenocarcinoma, serum PF-4 could be considered a prognostic factor for survival and increased risk for the development of venous thromboembolism [39]. This evidence concerns the gene PF4 and pancreatic adenocarcinoma.